Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.
JAMA Oncol · 2025-Jan-01 · PMID 39541202
overall survival
Figure 3.. Biomarker Analysis A and B, The associations of intratumor heterogeneity (ITH) with progression-free survival (PFS) and overall survival (OS) are shown. Patients with ITH-low tumors, as defined by a Mutant-Allele Tumor Heterogeneity score of less than 29, achieved significantly better PFS and OS from toripalimab plus chemotherapy. C and D, Kaplan-Meier–estimated PFS and OS curves compare the toripalimab plus chemotherapy group with the placebo plus chemotherapy group between HLA-A11 + HLA-B62 − and HLA-A11 − HLA-B62 + / HLA-A11 + HLA-B62 + / HLA-A11 − HLA-B62 − subgroups. Patients with HLA-A11 + HLA-B62 − haplotype had more favorable outcomes from toripalimab plus chemotherapy. The P for interaction values of the subgroup variables were computed using the Cox proportional hazards regression model. NR indicates not reached.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 4 | 2026-07-23T18:22:52+00:00 |